Patents on Small-Molecule Drugs Approved by the US Food and Drug Administration, 1990-2019
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
These portfolios have largely been built on nonprimary patents, which are then enforced against generic firms at higher rates than primary patents.
Appeared: Wednesday, September 30. JAMA. Peer-reviewed journal.